Cyclin D1 and retinoblastoma susceptibility gene alterations in non- small cell lung cancer

Antonio Marchetti, Claudio Doglioni, Mattia Barbareschi, Fiamma Buttitta, Silvia Pellegrini, Patrizia Gaeta, Roberto La Rocca, Giorgio Merlo, Antonio Chella, Carlo Alberto Angeletti, Paolo Dalla Palma, Generoso Bevilacqua

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Among the major regulators of the G 1 restriction point are cyclin D1 and the retinoblastoma gene product (RB). In non-small cell lung cancer (NSCLC), the cyclin D1 gene is amplified/over-expressed in almost 50% of cases, and RB is inactivated in 6-32% of cases. It is of interest to evaluate concurrently the alterations of both genes on the same series of NSCLCs, to investigate whether cyclin D1 and RB alterations are alternative pathways leading to inactivation of the G 1 restriction point or if they can occur in the same tumor, possibly exerting an additive effect on cancer progression. We investigated a series of 57 NSCLCs, analyzing cyclin D1 and RB at the gene and protein levels by Southern blot, Northern blot and immunohistochemistry. The cyclin D1 gene was amplified in 18 cases, cyclin D1 immunoreactivity was seen in 25 tumors. Amplification and expression were significantly associated. RB immunohistochemical expression was absent in 9 of 42 informative cases. RB mRNA expression was low to absent in 9 of 45 informative cases. cyclin D1 amplification was associated with normal RB mRNA, and cyclin D1 over-expression was associated with normal RB immunoreactivity, supporting the hypothesis that alterations of cyclin D1 and RB are alternative mechanisms by which tumor cells may escape the G 1 restriction point. A concurrent alteration of RB and cyclin D1 was seen in a small subset of NSCLCs. Abnormalities of cyclin D1 and/or RB at the gene and/or expression level were present in more than 90% of cases, stressing that cyclin D1 and/or RB alterations represent an important step in lung tumorigenesis.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalInternational Journal of Cancer
Volume75
Issue number2
DOIs
Publication statusPublished - Jan 19 1998

Fingerprint

Retinoblastoma Genes
Cyclin D1
Non-Small Cell Lung Carcinoma
bcl-1 Genes
Neoplasms
Messenger RNA
Southern Blotting
Northern Blotting
Carcinogenesis
Immunohistochemistry
Gene Expression
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cyclin D1 and retinoblastoma susceptibility gene alterations in non- small cell lung cancer. / Marchetti, Antonio; Doglioni, Claudio; Barbareschi, Mattia; Buttitta, Fiamma; Pellegrini, Silvia; Gaeta, Patrizia; La Rocca, Roberto; Merlo, Giorgio; Chella, Antonio; Angeletti, Carlo Alberto; Palma, Paolo Dalla; Bevilacqua, Generoso.

In: International Journal of Cancer, Vol. 75, No. 2, 19.01.1998, p. 187-192.

Research output: Contribution to journalArticle

Marchetti, A, Doglioni, C, Barbareschi, M, Buttitta, F, Pellegrini, S, Gaeta, P, La Rocca, R, Merlo, G, Chella, A, Angeletti, CA, Palma, PD & Bevilacqua, G 1998, 'Cyclin D1 and retinoblastoma susceptibility gene alterations in non- small cell lung cancer', International Journal of Cancer, vol. 75, no. 2, pp. 187-192. https://doi.org/10.1002/(SICI)1097-0215(19980119)75:2<187::AID-IJC4>3.0.CO;2-Q
Marchetti, Antonio ; Doglioni, Claudio ; Barbareschi, Mattia ; Buttitta, Fiamma ; Pellegrini, Silvia ; Gaeta, Patrizia ; La Rocca, Roberto ; Merlo, Giorgio ; Chella, Antonio ; Angeletti, Carlo Alberto ; Palma, Paolo Dalla ; Bevilacqua, Generoso. / Cyclin D1 and retinoblastoma susceptibility gene alterations in non- small cell lung cancer. In: International Journal of Cancer. 1998 ; Vol. 75, No. 2. pp. 187-192.
@article{cde3f6bc56f5483c8b9e3459bdfeb389,
title = "Cyclin D1 and retinoblastoma susceptibility gene alterations in non- small cell lung cancer",
abstract = "Among the major regulators of the G 1 restriction point are cyclin D1 and the retinoblastoma gene product (RB). In non-small cell lung cancer (NSCLC), the cyclin D1 gene is amplified/over-expressed in almost 50{\%} of cases, and RB is inactivated in 6-32{\%} of cases. It is of interest to evaluate concurrently the alterations of both genes on the same series of NSCLCs, to investigate whether cyclin D1 and RB alterations are alternative pathways leading to inactivation of the G 1 restriction point or if they can occur in the same tumor, possibly exerting an additive effect on cancer progression. We investigated a series of 57 NSCLCs, analyzing cyclin D1 and RB at the gene and protein levels by Southern blot, Northern blot and immunohistochemistry. The cyclin D1 gene was amplified in 18 cases, cyclin D1 immunoreactivity was seen in 25 tumors. Amplification and expression were significantly associated. RB immunohistochemical expression was absent in 9 of 42 informative cases. RB mRNA expression was low to absent in 9 of 45 informative cases. cyclin D1 amplification was associated with normal RB mRNA, and cyclin D1 over-expression was associated with normal RB immunoreactivity, supporting the hypothesis that alterations of cyclin D1 and RB are alternative mechanisms by which tumor cells may escape the G 1 restriction point. A concurrent alteration of RB and cyclin D1 was seen in a small subset of NSCLCs. Abnormalities of cyclin D1 and/or RB at the gene and/or expression level were present in more than 90{\%} of cases, stressing that cyclin D1 and/or RB alterations represent an important step in lung tumorigenesis.",
author = "Antonio Marchetti and Claudio Doglioni and Mattia Barbareschi and Fiamma Buttitta and Silvia Pellegrini and Patrizia Gaeta and {La Rocca}, Roberto and Giorgio Merlo and Antonio Chella and Angeletti, {Carlo Alberto} and Palma, {Paolo Dalla} and Generoso Bevilacqua",
year = "1998",
month = "1",
day = "19",
doi = "10.1002/(SICI)1097-0215(19980119)75:2<187::AID-IJC4>3.0.CO;2-Q",
language = "English",
volume = "75",
pages = "187--192",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Cyclin D1 and retinoblastoma susceptibility gene alterations in non- small cell lung cancer

AU - Marchetti, Antonio

AU - Doglioni, Claudio

AU - Barbareschi, Mattia

AU - Buttitta, Fiamma

AU - Pellegrini, Silvia

AU - Gaeta, Patrizia

AU - La Rocca, Roberto

AU - Merlo, Giorgio

AU - Chella, Antonio

AU - Angeletti, Carlo Alberto

AU - Palma, Paolo Dalla

AU - Bevilacqua, Generoso

PY - 1998/1/19

Y1 - 1998/1/19

N2 - Among the major regulators of the G 1 restriction point are cyclin D1 and the retinoblastoma gene product (RB). In non-small cell lung cancer (NSCLC), the cyclin D1 gene is amplified/over-expressed in almost 50% of cases, and RB is inactivated in 6-32% of cases. It is of interest to evaluate concurrently the alterations of both genes on the same series of NSCLCs, to investigate whether cyclin D1 and RB alterations are alternative pathways leading to inactivation of the G 1 restriction point or if they can occur in the same tumor, possibly exerting an additive effect on cancer progression. We investigated a series of 57 NSCLCs, analyzing cyclin D1 and RB at the gene and protein levels by Southern blot, Northern blot and immunohistochemistry. The cyclin D1 gene was amplified in 18 cases, cyclin D1 immunoreactivity was seen in 25 tumors. Amplification and expression were significantly associated. RB immunohistochemical expression was absent in 9 of 42 informative cases. RB mRNA expression was low to absent in 9 of 45 informative cases. cyclin D1 amplification was associated with normal RB mRNA, and cyclin D1 over-expression was associated with normal RB immunoreactivity, supporting the hypothesis that alterations of cyclin D1 and RB are alternative mechanisms by which tumor cells may escape the G 1 restriction point. A concurrent alteration of RB and cyclin D1 was seen in a small subset of NSCLCs. Abnormalities of cyclin D1 and/or RB at the gene and/or expression level were present in more than 90% of cases, stressing that cyclin D1 and/or RB alterations represent an important step in lung tumorigenesis.

AB - Among the major regulators of the G 1 restriction point are cyclin D1 and the retinoblastoma gene product (RB). In non-small cell lung cancer (NSCLC), the cyclin D1 gene is amplified/over-expressed in almost 50% of cases, and RB is inactivated in 6-32% of cases. It is of interest to evaluate concurrently the alterations of both genes on the same series of NSCLCs, to investigate whether cyclin D1 and RB alterations are alternative pathways leading to inactivation of the G 1 restriction point or if they can occur in the same tumor, possibly exerting an additive effect on cancer progression. We investigated a series of 57 NSCLCs, analyzing cyclin D1 and RB at the gene and protein levels by Southern blot, Northern blot and immunohistochemistry. The cyclin D1 gene was amplified in 18 cases, cyclin D1 immunoreactivity was seen in 25 tumors. Amplification and expression were significantly associated. RB immunohistochemical expression was absent in 9 of 42 informative cases. RB mRNA expression was low to absent in 9 of 45 informative cases. cyclin D1 amplification was associated with normal RB mRNA, and cyclin D1 over-expression was associated with normal RB immunoreactivity, supporting the hypothesis that alterations of cyclin D1 and RB are alternative mechanisms by which tumor cells may escape the G 1 restriction point. A concurrent alteration of RB and cyclin D1 was seen in a small subset of NSCLCs. Abnormalities of cyclin D1 and/or RB at the gene and/or expression level were present in more than 90% of cases, stressing that cyclin D1 and/or RB alterations represent an important step in lung tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=17144465526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144465526&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19980119)75:2<187::AID-IJC4>3.0.CO;2-Q

DO - 10.1002/(SICI)1097-0215(19980119)75:2<187::AID-IJC4>3.0.CO;2-Q

M3 - Article

VL - 75

SP - 187

EP - 192

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -